- Home
- SJT vs PALI Comparison
SJT vs PALI Comparison
Compare SJT & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$1.73
Company Overview
Basic Information| Metric | SJT | PALI |
|---|---|---|
| Founded | 1980 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.8M | 240.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | SJT | PALI |
|---|---|---|
| Price | $5.66 | $1.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 218.0K | ★ 4.6M |
| Earning Date | 03-30-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $24,557.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.12 | $0.53 |
| 52 Week High | $7.22 | $2.64 |
Technical Indicators
Market Signals| Indicator | SJT | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 46.31 | 49.72 |
| Support Level | $5.45 | $1.65 |
| Resistance Level | $5.75 | $1.84 |
| Average True Range (ATR) | 0.19 | 0.13 |
| MACD | -0.04 | 0.02 |
| Stochastic Oscillator | 29.84 | 77.50 |
Price Performance
Historical Comparison SJT
PALI
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.